Clinical Evaluation of human embryonic stem cells (hESCs) induced with directed differentiation to gonadotrope cells to cure vasculogenic impotency and to improve coital frequency in males. An open st
Poster Nov 03, 2009
This work demonstrates the clinical efficacy, tolerability and safety of patient-syngenic hESC induced with directed differentiation to gonadotrope cells. Hypothalamus transmits gonadotropin releasing factor to pituitary that sets off LH and FSH to Sertoli cell and Seminiferous tubule resulting Leydig cell to produces testosterone. This potential offers a rationale to evaluate hESCs to cure patients with vasculogenic impotency and to improve coital frequency in males.
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE
Patients with partial deficiency of recombination-activating genes 1 or 2 (RAG1/2) can present with a wide spectrum of primary immunodeficiencies including combined immunodeficiency with granuloma and/or autoimmunity (CID-G/AI). Prior case reports have highlighted alterations in B and T cell compartments; however comprehensive characterization of these cell populations with focus on autoreactive-prone subsets has not been reported.READ MORE